Physician profile
Deepa Subramanian
NPI 1588744429
$639.14
in general payments reported to CMS, 2019-2025
13 companies · $85.24 in 2025
The $85.24 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.38 · 2020: $120 · 2021: $199 · 2022: $11.71 · 2023: $77.84 · 2024: $98.17 · 2025: $85.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $261.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $119.10 | 2020-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $107.69 | 2019-2021 | |
| Ucb, INC. | $85.59 | 2020-2021 | |
| Astellas Pharma US INC | $69.75 | 2020-2021 | |
| Leo Pharma INC. | $62.95 | 2025 | Spevigo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.01 | 2023 | Jardiance |
| Lilly USA, LLC | $36.46 | 2023-2024 | Mounjaro |
| Merck Sharp & Dohme LLC | $22.11 | 2020 | |
| Sumitomo Pharma America, INC. | $21.56 | 2024 | Gemtesa |
| Amarin Pharma, INC. | $20.66 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.62 | 2019 | |
| Pfizer INC. | $16.05 | 2023 | |
| Boston Scientific Corporation | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepa Subramanian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.